What considerations should be taken when designing experiments using the anti-Rat IgG(Fc)Fab-C-MMAE ADC?

Experiment design should consider the concentration of ADC, the expression levels of the target antigen, and the sensitivity of the detection methods. Optimization of these factors is crucial to maximize the ADC's effectiveness while ensuring reproducible and reliable results.

How does the anti-Rat IgG(Fc)Fab-C-MMAE ADC contribute to the pre-screening of rat monoclonal antibodies as ADC candidates?

The ADC provides a robust platform for evaluating the therapeutic potential of rat monoclonal antibodies. By using this tool, researchers can efficiently test the binding and cytotoxic properties of new antibodies in a cost-effective manner, significantly speeding up the early stages of ADC development.

How does the ADC's targeting mechanism facilitate its use in targeted drug delivery research?

The targeting mechanism of the anti-Rat IgG(Fc)Fab-C-MMAE ADC, which focuses on cells expressing the rat IgG Fc region, enables precise delivery of the cytotoxic agent MMAE. This specificity is critical in research focused on developing targeted drug delivery systems that minimize off-target effects and enhance therapeutic outcomes.

What experimental conditions affect the efficacy of the anti-Rat IgG(Fc)Fab-C-MMAE ADC in preclinical studies?

The efficacy of the ADC in preclinical studies is influenced by variables such as the expression level of the target antigen on the cell surface, the incubation period of the ADC with target cells, and the physiological condition of the cell culture. Optimizing these conditions is essential to fully harness the ADC's potential in targeted cancer therapy models.

What specific role does the anti-Rat IgG(Fc)Fab-C-MMAE ADC play in the validation of rat-derived therapeutic antibodies?

The anti-Rat IgG(Fc)Fab-C-MMAE ADC is instrumental in validating the binding and cytotoxicity of rat-derived therapeutic antibodies. By targeting cells that express the Fc region of rat IgG, this ADC allows researchers to ascertain the therapeutic potential and specificity of new rat antibodies in a controlled laboratory environment.

Home
Products
Anti-Ab ADCs
IgG Fc
anti-Rat IgG(Fc)Fab-C-MMAE ADC

anti-Rat IgG(Fc)Fab-C-MMAE ADC (CAT#: ADC-AA-043)

This ADC product is comprised of a Fab fragment of an anti-rat IgG Fc specific polyclonal antibody conjugated via a cleavable linker to MMAE. The antibody portion is a Fab fragment of a secondary antibody and the drug portion, MMAE, is a cytotoxic small molecule which binds to tubulins, interrupts microtubule dynamics, and induces cell death. This product displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening rat monoclonal antibodies as ADC candidates.

ADC Target
ADC Antibody
ADC Linker
ADC payload drug

Name
IgG Fc

Overview
The fragment crystallizable region (Fc region) is composed of the constant region of the two heavy chains that form the IgG molecule. The Fc region of IgG bears a highly conserved N-glycosylation site. Glycosylation of the Fc fragment is essential for Fc receptor-mediated activity. Fc binds to various cell receptors and complement proteins thus mediating different physiological effects of antibodies, such as opsonization, antibody dependent cellular cytotoxicity (ADCC), degranulation of mast cells, basophils, eosinophils and other processes.

Overview
Fab fragment of anti-rat IgG Fc specific polyclonal antibody

Species Reactivity
Rat

Name
Cleavable linkers

Description
Cleavable linkers rely on the physiological stimuli, which mainly include chemically cleavable linkers and enzymatically cleavable linkers. Chemically cleavable linkers including acid-labile linkers and disulfide linkers. For acid-labile linkers, intracellular release of payloads relies on the different pH between endosomes/lysosomes and blood. The release of disulﬁde-linked drugs is controlled by the factors in intracellular environment. Enzymatically cleavable linkers, peptide linkers and β-glucuronide linkers, are sensitive to enzymes located in cytoplasm.

Name
MMAE (Monomethyl auristatin E)

Description
Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.

For Research Use Only. NOT FOR CLINICAL USE.

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform

Reviews

Literature

Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-AA-043. Click the button above to contact us or submit your feedback about this product.

Customer Reviews FAQ

Excellent

The anti-Rat IgG(Fc)Fab-C-MMAE ADC has significantly improved our antibody screenings. The cleavable linker to MMAE ensures precise cytotoxicity with minimal background noise, making our experiments both efficient and reliable.

Excellent

We've been very impressed with the performance of the anti-Rat IgG(Fc)Fab-C-MMAE ADC. The product's specificity and the cytotoxic effects of MMAE have been consistent in every assay we've conducted.

Excellent

The anti-Rat IgG(Fc)Fab-C-MMAE ADC exceeded our expectations with its strong performance and safety profile. The product delivered consistent cytotoxicity, which was crucial for our pre-screening processes.

Excellent

Highly recommend this ADC!

The cleavable linker and MMAE work seamlessly together, providing accurate and efficient results in our screenings. Plus, the low toxicity is a major advantage for our research.

Excellent

The anti-Rat IgG(Fc)Fab-C-MMAE ADC from Creative Biolabs has proven to be a reliable tool in our lab. The product's specificity, paired with the low toxicity of the MMAE, has made it a preferred choice for our research.

Q: 1: What considerations should be taken when designing experiments using the anti-Rat IgG(Fc)Fab-C-MMAE ADC?
A: Experiment design should consider the concentration of ADC, the expression levels of the target antigen, and the sensitivity of the detection methods. Optimization of these factors is crucial to maximize the ADC's effectiveness while ensuring reproducible and reliable results.
Q: 2: How does the anti-Rat IgG(Fc)Fab-C-MMAE ADC contribute to the pre-screening of rat monoclonal antibodies as ADC candidates?
A: The ADC provides a robust platform for evaluating the therapeutic potential of rat monoclonal antibodies. By using this tool, researchers can efficiently test the binding and cytotoxic properties of new antibodies in a cost-effective manner, significantly speeding up the early stages of ADC development.
Q: 3: How does the ADC's targeting mechanism facilitate its use in targeted drug delivery research?
A: The targeting mechanism of the anti-Rat IgG(Fc)Fab-C-MMAE ADC, which focuses on cells expressing the rat IgG Fc region, enables precise delivery of the cytotoxic agent MMAE. This specificity is critical in research focused on developing targeted drug delivery systems that minimize off-target effects and enhance therapeutic outcomes.
Q: 4: What experimental conditions affect the efficacy of the anti-Rat IgG(Fc)Fab-C-MMAE ADC in preclinical studies?
A: The efficacy of the ADC in preclinical studies is influenced by variables such as the expression level of the target antigen on the cell surface, the incubation period of the ADC with target cells, and the physiological condition of the cell culture. Optimizing these conditions is essential to fully harness the ADC's potential in targeted cancer therapy models.
Q: 5: What specific role does the anti-Rat IgG(Fc)Fab-C-MMAE ADC play in the validation of rat-derived therapeutic antibodies?
A: The anti-Rat IgG(Fc)Fab-C-MMAE ADC is instrumental in validating the binding and cytotoxicity of rat-derived therapeutic antibodies. By targeting cells that express the Fc region of rat IgG, this ADC allows researchers to ascertain the therapeutic potential and specificity of new rat antibodies in a controlled laboratory environment.

Quick Links

ADC Toxins

Drug-linker Complexes

Customized ADCs

Anti-Ab ADCs

Other Products

Same Target Same Linker Same Payload

CAT#	Product Name	Linker	Payload
ADC-AA-049	Protein G-MMAF ADC		MMAF (Monomethyl auristatin F)
ADC-AA-026	anti-MIgG(Fc)-N-DM1 ADC	Noncleavable linkers	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-027	anti-MIgG(Fc)Fab-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-031	anti-MIgG(Fc)Fab-N-DM1 ADC	Noncleavable linkers	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-021	anti-MIgG(Fc)-C-MMAE ADC	Cleavable linkers	MMAE (Monomethyl auristatin E)

CAT#	Product Name	Linker	Payload
ADC-AA-062	Anti-HIgG(Fc)Fab-C-DX8951 ADC	Cleavable linkers	DX8953
ADC-AA-020	anti-MIgG(Fc)-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-011	anti-HIgG(Fc)Fab-C-MMAE ADC	Cleavable linkers	MMAE (Monomethyl auristatin E)
ADC-AA-066	Anti-Rat IgG(H+L)-C-PBD ADC	Cleavable linkers	PBD (pyrrolobenzodiazepine)
WJY-0423-LS108	Protein G-Amanitin ADC	Cleavable linkers	Amanitin

CAT#	Product Name	Linker	Payload
ADC-AA-003	anti-HIgG(Fc)-C-MMAE ADC	Cleavable linkers	MMAE (Monomethyl auristatin E)
ADC-AA-056	Anti-MIgG-VC-MMAE ADC	VC (valine-citrulline)	MMAE (Monomethyl auristatin E)
ADC-W-529	Anti-F3-VC-MMAE ADC-6	VC (valine-citrulline)	MMAE (Monomethyl auristatin E)
ADC-W-536	Anti-EDNRB (endothelin B)-VC-MMAE ADC	VC (valine-citrulline)	MMAE (Monomethyl auristatin E)
ADC-W-462	Anti-GPNMB-VC-MMAE ADC	VC (valine-citrulline)	MMAE (Monomethyl auristatin E)

Online Inquiry

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.